Cellular Dynamics International, Inc. (CDI), the world’s largest commercial producer of human induced pluripotent stem (iPS) cell lines and tissue cells, today announced the launch of its MyCell™ Services. These services include novel iPS cell line reprogramming, genetic engineering and differentiation of iPS cells into commercially available iCell® terminal tissue cells (for example, heart or nerve cells).
“CDI’s mission is to be the top developer and manufacturer of standardized human cells in high quantity, quality and purity and to make these cells widely available to the research community. Our MyCell Services provide researchers with unprecedented access to the full diversity
Scientists at the UCSF-affiliated Gladstone Institutes have for the first time transformed skin cells — with a single genetic factor — into cells that develop on their own into an interconnected, functional network of brain cells.
The research offers new hope in the fight against many neurological conditions because scientists expect that such a transformation — or reprogramming — of cells may lead to better models for testing drugs for devastating neurodegenerative conditions such as Alzheimer’s disease.
This research comes at a time of renewed focus on Alzheimer’s disease, which currently afflicts 5.4 million people in the United States alone —
The team at Children’s Hospital Boston and the Harvard Stem Cell Institute were working with a new type of cell called induced pluripotent stem cells or iPS cells, which closely resemble embryonic stem cells but are made from ordinary skin cells.
In this case, they wanted to study a rare, inherited premature aging disorder called dyskeratosis congenita. The blood marrow disorder resembles the better-known aging disease progeria and causes premature graying, warped fingernails and other symptoms as well as a high risk of cancer.
One of the benefits of stem cells and iPS cells is that researchers can make them from
Image by engineroomblog via Flickr
Using skin cells from people with type 1 diabetes, researchers were able to produce cells that made insulin in response to changing blood sugar levels, though not as efficiently as normal insulin-producing cells do. (…) “This is a big deal,” said Susan Solomon, CEO of the New York Stem Cell Foundation, which provided some of the funding for the study. “Tackling the basic biology of type 1 diabetes, which is a very complex disease, is a critical step. With these cells, we can see in a dish what’s happening to the immune system, and if
In a landmark paper, researchers at Stanford University have described a new way to derive human induced pluripotent stem cells (iPSCs) without the use of contaminating mouse feeder cells. Using adipose cells as the starting cell population and mTeSR1, a defined medium that allows the expansion of human embryonic and induced pluripotent stem cells without the use of feeders, the researchers were able to fully reprogram the cells to the pluripotent state.
mTeSR1 is a fully defined medium and is the most widely used feeder-independent method for culturing human pluripotent stem cells, with citations in more than 25 publications.